This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

LabCorp To Offer BRCAssureSM Breast Cancer Mutation Tests

Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH) announced today the nationwide availability of a suite of tests to identify patients with BRCA mutations who are at increased risk for breast, ovarian and other cancers. The BRCA ssure tests will be available through LabCorp as well as Integrated Genetics and Integrated Oncology, members of LabCorp’s Specialty Testing Group.

The vast majority of individuals with hereditary breast and ovarian cancer syndrome, as well as a significant percentage of all diagnosed breast cancers, exhibit mutations in the BRCA1 and BRCA2 genes. In addition, men and women with mutations in BRCA1 or BRCA2 may also have increased risk of other cancers, including pancreatic, prostate, melanoma, stomach, esophageal and bile duct cancers.

LabCorp’s Comprehensive BRCA ssure BRCA1/2 Analysis will include full gene sequencing of BRCA1/2 genes and duplication/deletion testing, with a variant of unknown significance (VUS) rate of less than five percent (5%). Once a mutation is identified, family members can be tested for the known mutations using the BRCA ssure BRCA1 or BRCA ssure BRCA2 Targeted Analysis tests. In addition, LabCorp offers a separate panel for mutations prevalent among people of Ashkenazi Jewish descent. The BRCA ssure Ashkenazi Jewish Panel includes screening for three known pathogenic variants: two in the BRCA1 gene, and one in the BRCA2 gene. These three mutations have a combined frequency of approximately 2% in the Jewish population.

“The National Comprehensive Cancer Network and the American College of Obstetricians and Gynecologists recognize the importance of screening for BRCA 1 and BRCA2 mutations, and LabCorp's BRCA ssure panels will make this testing more available," stated Dr. Mark Brecher, LabCorp's Chief Medical Officer. “LabCorp’s comprehensive, full gene sequencing BRCA ssure tests will give healthcare providers the mutation information necessary to assist in patient counseling.”

A leader in genetic testing and counseling services for more than 25 years, LabCorp’s BRCA testing capabilities and services provide physicians and patients powerful tools for the assessment of breast cancer risk. With 145 genetic counselors on staff, LabCorp offers the broadest team of professionals trained to analyze, assess and interpret genetic test results. Combined with LabCorp's Care Coordination preauthorization service, the Company offers an end-to-end program for patients and physicians including compliance with insurance requirements, comprehensive testing, and expert interpretation.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs